Compare TCX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | MDWD |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | Canada | Israel |
| Employees | N/A | 121 |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 193.3M |
| IPO Year | 2005 | 2013 |
| Metric | TCX | MDWD |
|---|---|---|
| Price | $15.64 | $15.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 31.6K | ★ 68.5K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | N/A |
| Revenue This Year | N/A | $48.88 |
| Revenue Next Year | N/A | $35.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $13.27 | $14.14 |
| 52 Week High | $25.17 | $22.51 |
| Indicator | TCX | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 31.36 |
| Support Level | $15.50 | N/A |
| Resistance Level | $22.15 | $18.58 |
| Average True Range (ATR) | 0.78 | 0.59 |
| MACD | 0.15 | -0.15 |
| Stochastic Oscillator | 23.58 | 10.15 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. Geographically company operates in USA, Canada and Europe.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.